PXMD

PaxMedica Inc. (PXMD) | Rumor.io

PaxMedica

PXMD

Attention (50-day avg)0%

Attention rank (50-day avg)#4,982

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization63.1K

Earnings per share2.44

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-18.3M

Social

What share of all stock conversation is about PXMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 2

PaxMedica, Inc. has been subject to trading halts and suspensions, with some speculating it may be related to pending material news.
The company's NDA submission was reportedly on track, but some investors are questioning the timing and potential manipulation.
There is speculation about the potential for a buyout of PaxMedica, with some investors hoping for a turnaround in the company's fortunes.

Generated by AI

Sentiment

Of the messages about PXMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	73.33% +37.62
Bearish	—	—	0%	26.67% -37.62

Bullish· Apr 17

Analysts are bullish on $PXMD, with a target price of $3.00 and a strong buy rating, driven by immigration-related growth.
$PXMD has a positive technical analysis, with a breakout above a near-term pullback and a positive MACD indicator, suggesting a potential upside.
The company's strong balance sheet, with more cash than debt, and the potential for a PR announcement aiding Africa, are creating a good setup for a price increase.

Bearish· Apr 12

The stock has been oversold and is due for a reversal.
The company is experiencing dilution, which may impact shareholder value.
The stock is at risk of a gap fill or a significant price drop if it fails to break through a key resistance level.

Generated by AI

Topics

Of the messages about PXMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	85.71%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	14.29%

Announcements· Nov 7

PaxMedica, Inc. (PXMD) announced the publication of its Autism Spectrum Disorder Phase 2 study results in a peer-reviewed journal, which may have a positive impact on the stock.
Trading for PXMD was halted multiple times on November 7, 2023, but has since been resumed, indicating significant market activity around the company's announcements.
The stock price of PXMD increased by 108% on November 7, 2023, following the announcement of the publication of its Autism Spectrum Disorder Phase 2 study results.

Technical Analysis· Sep 2

$PXMD has seen a 42% gain from the 4.50 break, with a target of 7.00.
Key levels for $PXMD include resistance near $6.58 and $7.05, and support near previous levels under $5.77.
A VWAP crossover has been observed in $PXMD, with a retest that holds potentially indicating further gains.

Generated by AI

Community

Of the messages about PXMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	26.92%
Newcomers	—	—	0%	73.08%

Regulars· Nov 20

The current stock price of $PXMD is around $1.07, and there are multiple catalysts incoming that could drive the price up.
The float of $PXMD is small, and the author believes it could be a good buying opportunity, with a target price of $1.20.
$PXMD's stock price has touched an all-time low after a recent stock offering, but the author believes it could turn green and become a buying opportunity soon.

Newcomers· Nov 20

New investors are focused on PaxMedica's (PXMD) recent $7 million public offering, which may be used to advance the company's development programs.
Some newcomers are concerned about the 40% decline in PaxMedica's stock price, with the recent public offering being cited as a possible reason.
Investors are also interested in PaxMedica's (PXMD) upcoming FDA Type-B meeting, which may have significant implications for the company's development programs.

Generated by AI

Also Discussed

Investors talking about PXMD also mention

#	Name	Attention
1	NVOS - Novo Integrated Sciences, Inc.	——
2	Jianzhi Education Technology Group Company Limited ADRJZ	0%+0
3	PBLA - Panbela Therapeutics, Inc.	——
4	NRBO - NeuroBo Pharmaceuticals, Inc.	——
5	SECO - Secoo Holding Limited	——
6	Cosmos Health Inc.COSM	0.02%+0.01
7	BioAffinity Technologies Inc.BIAF	0%+0
8	Digital Brands Group, Inc. Common StockDBGI	0%0
9	MRAI - Marpai, Inc.	——
10	BRDS - Bird Global, Inc.	——

PaxMedica Inc.

Healthcare
Biotechnology

PaxMedica Inc. is a clinical-stage biopharmaceutical company primarily focused on developing therapeutics for the treatment of complex neurological and developmental disorders. The company is heavily engaged in the research and development of innovative drug therapeutics aimed at addressing autism spectrum disorder and related conditions. PaxMedica Inc. leverages its expertise in the field to create compounds that target the specific biological pathways implicated in these disorders, seeking to offer new treatment options. Operating at the intersection of cutting-edge science and unmet medical needs, the company's mission is to enhance the quality of life for patients through improved management of neurological complications. As a player in the biopharmaceutical sector, PaxMedica Inc. holds significant potential for impact in the medical and healthcare industries by potentially providing breakthroughs in markets where there currently exist few effective treatments.

Website

Location

303 South Broadway

Tarrytown, NY, 10591

United States

Social

What share of all stock conversation is about PXMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 2

PaxMedica, Inc. has been subject to trading halts and suspensions, with some speculating it may be related to pending material news.
The company's NDA submission was reportedly on track, but some investors are questioning the timing and potential manipulation.
There is speculation about the potential for a buyout of PaxMedica, with some investors hoping for a turnaround in the company's fortunes.

Generated by AI

Sentiment

Of the messages about PXMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	73.33% +37.62
Bearish	—	—	0%	26.67% -37.62

Bullish· Apr 17

Analysts are bullish on $PXMD, with a target price of $3.00 and a strong buy rating, driven by immigration-related growth.
$PXMD has a positive technical analysis, with a breakout above a near-term pullback and a positive MACD indicator, suggesting a potential upside.
The company's strong balance sheet, with more cash than debt, and the potential for a PR announcement aiding Africa, are creating a good setup for a price increase.

Bearish· Apr 12

The stock has been oversold and is due for a reversal.
The company is experiencing dilution, which may impact shareholder value.
The stock is at risk of a gap fill or a significant price drop if it fails to break through a key resistance level.

Generated by AI

Topics

Of the messages about PXMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	85.71%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	14.29%

Announcements· Nov 7

PaxMedica, Inc. (PXMD) announced the publication of its Autism Spectrum Disorder Phase 2 study results in a peer-reviewed journal, which may have a positive impact on the stock.
Trading for PXMD was halted multiple times on November 7, 2023, but has since been resumed, indicating significant market activity around the company's announcements.
The stock price of PXMD increased by 108% on November 7, 2023, following the announcement of the publication of its Autism Spectrum Disorder Phase 2 study results.

Technical Analysis· Sep 2

$PXMD has seen a 42% gain from the 4.50 break, with a target of 7.00.
Key levels for $PXMD include resistance near $6.58 and $7.05, and support near previous levels under $5.77.
A VWAP crossover has been observed in $PXMD, with a retest that holds potentially indicating further gains.

Generated by AI

Community

Of the messages about PXMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	26.92%
Newcomers	—	—	0%	73.08%

Regulars· Nov 20

The current stock price of $PXMD is around $1.07, and there are multiple catalysts incoming that could drive the price up.
The float of $PXMD is small, and the author believes it could be a good buying opportunity, with a target price of $1.20.
$PXMD's stock price has touched an all-time low after a recent stock offering, but the author believes it could turn green and become a buying opportunity soon.

Newcomers· Nov 20

New investors are focused on PaxMedica's (PXMD) recent $7 million public offering, which may be used to advance the company's development programs.
Some newcomers are concerned about the 40% decline in PaxMedica's stock price, with the recent public offering being cited as a possible reason.
Investors are also interested in PaxMedica's (PXMD) upcoming FDA Type-B meeting, which may have significant implications for the company's development programs.

Generated by AI

PaxMedica

Social

May 2

Sentiment

Bullish· Apr 17

Bearish· Apr 12

Topics

Announcements· Nov 7

Technical Analysis· Sep 2

Community

Regulars· Nov 20

Newcomers· Nov 20

Also Discussed

PaxMedica Inc.

Company Information

Location

Also Discussed

Social

May 2

Sentiment

Bullish· Apr 17

Bearish· Apr 12

Topics

Announcements· Nov 7

Technical Analysis· Sep 2

Community

Regulars· Nov 20

Newcomers· Nov 20